FPR1 and melanoma: Collectively, our findings identify uPAR and FPR1 as novel prognostic markers and therapeutic targets in melanoma and indicate that inhibitors of the uPAR84–95/FPR1 cross-talk may be useful for the treatment of metastatic melanoma.